Seeking Alpha

LSYMD's  Instablog

LSYMD
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • ASCO Meeting 0 comments
    May 29, 2014 3:04 PM | about stocks: MRK

    The ASCO meeting is about to get underway, with abstracts having been dissected and the plenary session awaited. Clearly, the hottest topic this year, and for the foreseeable future, is cancer immunotherapy. I am looking forward to Merck's data, as I perceive it to be the leader in this field. Otherwise, I do not expect a significant amount of stock reaction due to conference presentations. I believe that we are in the "second inning" of immunotherapy, and that it will greatly advance treatment for many cancers (high mutations, viral origin) as part of combination regimens over the next 10 years. Furthermore, approaches such as adoptive transfer of lymphocytes are also being investigated. Over time, great strides will be made, and by 2030 we shall marvel at the new paradigms.

    Len

    Disclosure: I am long MRK.

    Themes: Oncology Stocks: MRK
Back To LSYMD's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.